The intersection of EGFR and the Ras signaling pathway
作者： Marie Wislez , Jonathan M. Kurie
DOI: 10.1007/978-1-59745-356-1_7
关键词:
摘要: EGFR is a survival factor for variety of cancer cell types. The mechanism by which regulated and the downstream mediators that regulate are subjects ongoing research. Here we highlight one important aspect signaling, bi-directional interaction between Ras. We discuss mechanistic basis this interaction, its implications biology, potential importance as target therapy.
springer.com
sci-hub.st 参考文章(54)
A Levitzki, E Manser, H Maruta, H He, L Lim, Y Hirokawa, Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Cancer Journal. ,vol. 7, pp. 191- 202 ,(2001)
J. Downward, Prelude to an Anniversary for the RAS Oncogene Science. ,vol. 314, pp. 433- 434 ,(2006) , 10.1126/SCIENCE.1134727
S. Rodenhuis, S. S. Wagenaar, W. J. Mooi, A. J. M. Boot, R. J. C. Slebos, P. C. Van Bodegom, S. G. Evers, J. L. Bos, Incidence and Possible Clinical Significance of K- ras Oncogene Activation in Adenocarcinoma of the Human Lung Cancer Research. ,vol. 48, pp. 5738- 5741 ,(1988)
Leisa Johnson, Kim Mercer, Doron Greenbaum, Roderick T. Bronson, Denise Crowley, David A. Tuveson, Tyler Jacks, Somatic activation of the K-ras oncogene causes early onset lung cancer in mice Nature. ,vol. 410, pp. 1111- 1116 ,(2001) , 10.1038/35074129
John D. Minna, Adi Gazdar, Joyce E. Ohm, Denise Juroske, Jonathan R. Pollack, Michael Peyton, Kiyoshi Yanagisawa, Yuhui Huang, Joseph Amann, J. Stuart Salmon, Hisayuki Shigematsu, David P. Carbone, Pierre P. Massion, Shailaja Kalyankrishna, Young H. Kim, Jonathan M. Kurie, Luc Girard, Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer Cancer Research. ,vol. 65, pp. 226- 235 ,(2005)
Natacha Edme, Julian Downward, Jean-Paul Thiery, Brigitte Boyer, Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways. Journal of Cell Science. ,vol. 115, pp. 2591- 2601 ,(2002) , 10.1242/JCS.115.12.2591
Adi F. Gazdar, Shinichi Toyooka, Kazunori Tsukuda, Mitsune Tanimoto, Masahiro Tabata, Kouichi Ichimura, Masaaki Yano, Toshihide Tsuda, Hisayuki Shigematsu, Hiroshi Date, Kunitoshi Tomii, Nobuyoshi Shimizu, Hiroshi Ueoka, Motoi Aoe, Masaki Tokumo, Katsuyuki Kiura, The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers Clinical Cancer Research. ,vol. 11, pp. 1167- 1173 ,(2005)
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
Ami Citri, Kochupurakkal Bose Skaria, Yosef Yarden, The deaf and the dumb: the biology of ErbB-2 and ErbB-3 Experimental Cell Research. ,vol. 284, pp. 54- 65 ,(2003) , 10.1016/S0014-4827(02)00101-5